Second-line treatments
| . | R (n = 77), n (%) . | RL (n = 77), n (%) . | Total (N = 154), n (%) . |
|---|---|---|---|
| First new therapy after trial treatment | 46 (60) | 30 (39) | 76 (49) |
| Treatment type | |||
| R-bendamustine* | 14 (30) | 11 (37) | 24 (32) |
| R-CHOP | 10 (22) | 7 (23) | 17 (22) |
| R-chlorambucil† | 4 (9) | 4 (13) | 8 (11) |
| R-CVP | 3 (7) | 1 (3) | 4 (5) |
| R alone‡ | 2 (4) | 5 (17) | 7 (9) |
| Radiotherapy alone§ | 7 (15) | 2 (7) | 9 (12) |
| High-dose therapy/autologous SCT | 2 (4) | 0 | 2 (3) |
| Other‖ | 4 (9) | 0 | 4 (5) |
| Response after first new therapy | |||
| CR/CRu | 18 (39) | 7 (23) | 25 (33) |
| PR | 20 (43) | 11 (37) | 31 (41) |
| SD | 1 (2) | 2 (7) | 3 (4) |
| PD | 5 (11) | 5 (17) | 10 (13) |
| Not assessable | 2 (4) | 5 (17) | 7 (9) |
| . | R (n = 77), n (%) . | RL (n = 77), n (%) . | Total (N = 154), n (%) . |
|---|---|---|---|
| First new therapy after trial treatment | 46 (60) | 30 (39) | 76 (49) |
| Treatment type | |||
| R-bendamustine* | 14 (30) | 11 (37) | 24 (32) |
| R-CHOP | 10 (22) | 7 (23) | 17 (22) |
| R-chlorambucil† | 4 (9) | 4 (13) | 8 (11) |
| R-CVP | 3 (7) | 1 (3) | 4 (5) |
| R alone‡ | 2 (4) | 5 (17) | 7 (9) |
| Radiotherapy alone§ | 7 (15) | 2 (7) | 9 (12) |
| High-dose therapy/autologous SCT | 2 (4) | 0 | 2 (3) |
| Other‖ | 4 (9) | 0 | 4 (5) |
| Response after first new therapy | |||
| CR/CRu | 18 (39) | 7 (23) | 25 (33) |
| PR | 20 (43) | 11 (37) | 31 (41) |
| SD | 1 (2) | 2 (7) | 3 (4) |
| PD | 5 (11) | 5 (17) | 10 (13) |
| Not assessable | 2 (4) | 5 (17) | 7 (9) |
PD, progressive disease; PR, partial response; R-CHOP, R plus cyclophosphamide, doxorubicin, vincristine, and prednisone; R-CVP, R plus cyclophosphamide, vincristine, and prednisone; SCT, stem cell transplantation; SD, stable disease.
Including 1 patient receiving obinutuzumab and bendamustine (RL arm) and 3 receiving bendamustine alone (R arm, n = 2; RL arm, n = 1).
Including 1 patient receiving chlorambucil and prednisone (RL arm).
Administered either as new therapy after relapse/progression (R arm, n = 1; RL arm, n = 2) or as consolidation/maintenance after the trial treatment (R arm, n = 1; RL arm, n = 3).
Administered as new therapy after relapse/progression in all cases, with the exception of 1 patient in R arm who received consolidation radiotherapy after the trial treatment.
Including 1 patient receiving BEACOPP (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone) for Hodgkin lymphoma and 3 patients receiving experimental treatments in other clinical trials.